A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Conditions

• Endometrial Carcinosarcoma

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Pembrolizumab — DRUG
  Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
• Olaparib — DRUG
  Olaparib will be administered orally at 300 mg every 12 hours.

Study Details

The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.

Key Dates

Start date

Jan 27, 2022

Status verified

Apr 2026

Primary completion

Apr 24, 2026

Completion

Apr 24, 2026

Study Design

Enrollment

26 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Pembrolizumab with Olaparib
  Eligible patients will receive olaparib in combination with pembrolizumab. Olaparib will be administered orally at 300 mg every 12 hours. Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 24 weeks ]

Locations (6)

Find similar trials in Basking Ridge, NJ